{
    "clinical_study": {
        "@rank": "129278", 
        "arm_group": [
            {
                "arm_group_label": "AMG 357", 
                "arm_group_type": "Experimental", 
                "description": "AMG 357 is a small molecule for treatment of inflammatory disease"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to AMG 357 containing no active drug"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to evaluate the safety, tolerability, PK, PD, and food effect of AMG 357 in healthy\n      subjects"
        }, 
        "brief_title": "A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Inflammatory Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Adult subjects          between 25 and 55 years old\n\n          -  Body mass index (BMI)           between 18 and 32 kg/m2\n\n          -  Normal or clinically         acceptable physical examination, clinical laboratory\n             values, and ECG\n\n          -  Additional inclusion criteria apply\n\n        Exclusion Criteria:\n\n          -  Any history or evidence of a clinically significant disorder, condition or disease\n             that would pose a risk to subject safety.\n\n          -  Additional exclusion criteria apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695876", 
            "org_study_id": "20110246", 
            "secondary_id": "Inflammation"
        }, 
        "intervention": [
            {
                "arm_group_label": "AMG 357", 
                "description": "Oral administration available in varying dose strength.", 
                "intervention_name": "AMG 357", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo to AMG 357 containing no active drug", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand", 
                        "zip": "8011"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grafton, Auckland", 
                        "country": "New Zealand", 
                        "zip": "1010"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "New Zealand"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "New Zealand: Medsafe"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Examine the number of adverse events per subject, and subject incidence of clinically significant changes in physical examinations, vital signs, laboratory safety tests and electrocardiograms, after single and multiple dose administration of AMG 357 in healthy subjects.", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "up to 35 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695876"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measure the area under the plasma concentration curve versus time of AMG 357 after single and multiple dose administration in healthy subjects", 
                "measure": "Pharmacodynamics", 
                "safety_issue": "Yes", 
                "time_frame": "up to 35 days"
            }, 
            {
                "description": "To assess the effect of food on the PK parameters of AMG 357", 
                "measure": "Effect of Food on AMG 357", 
                "safety_issue": "No", 
                "time_frame": "up to 11 days"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}